Five-year remission without disease progression in a patient with relapsed/refractory multiple myeloma with extramedullary disease treated with LCAR-B38M chimeric antigen receptor T cells in the LEGEND-2 study: a case report

BACKGROUND: Multiple myeloma remains incurable despite treatment advancements over the last 20 years. LCAR-B38M Cells in Treating Relapsed/Refractory Multiple Myeloma was a phase 1, first-in-human, investigator-initiated study in relapsed/refractory multiple myeloma conducted at four sites in China....

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Bai-Yan, Zhao, Wan-Hong, Chen, Yin-Xia, Cao, Xing-Mei, Yang, Yun, Zhang, Yi-Lin, Wang, Fang-Xia, Zhang, Peng-Yu, Lei, Bo, Gu, Liu-Fang, Wang, Jian-Li, Bai, Ju, Xu, Yan, Wang, Xu-Geng, Zhang, Rui-Li, Wei, Li-Li, Zhuang, Qiu-Chuan, Fan, Frank, Zhang, Wang-Gang, He, Ai-Li, Liu, Jie
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9741775/
https://www.ncbi.nlm.nih.gov/pubmed/36496425
http://dx.doi.org/10.1186/s13256-022-03636-9

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9741775/
https://www.ncbi.nlm.nih.gov/pubmed/36496425
http://dx.doi.org/10.1186/s13256-022-03636-9

Ejemplares similares